Fredun Pharmaceuticals Reports Zero Deviation in Preferential Issue Proceeds for Q2 FY27
Fredun Pharmaceuticals Ltd · Others (Uncategorized) · 14 Nov 2026, 8:57 pm
Fredun Pharmaceuticals Reports Zero Deviation in Preferential Issue Proceeds for Q2 FY27 Fredun Pharmaceuticals confirmed nil deviation in utilizing ₹128.78 crore raised via preferential issue as of 30th Sep'26. Management-certified cumulative utilization stood at ₹97.56 crore, while Monitoring Agency CARE Ratings reported ₹101.34 crore. The ₹3.78 crore variance stems from accounting treatment differences regarding funds parked in cash credit accounts. Key cumulative deployments include ₹57.07 crore for working capital, ₹20.34 crore for strategic reserves, ₹11.50 crore for brand marketing, ₹6.98 crore for capex, ₹3.95 crore for contingencies, and ₹1.50 crore for R&D.
Original exchange filing (PDF)
More announcements from Fredun Pharmaceuticals Ltd
- Audio Recording Q2 & H1 FY27 Earnings Conference Call of Fredun Pharmaceuticals Limited. · 16 Nov 2026
- Outcome of the Board Meeting of 'Fredun Pharmaceuticals Limited' ('Company') pursuant to Regulation 30 of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. · 14 Nov 2026
- Report of Monitoring Agency on the use of proceeds raised through Preferential Allotment for the quarters ended March 31, 2026, June 30,2026 and September30, 2026. · 14 Nov 2026
- Intimation of Earnings Conference Call for the Quarter Q2 of FY27 · 16 Nov 2026
- Press Release · 06 Nov 2026
- Approval for National Stock Exchange of India Limited (NSE) Listing Application. · 05 Nov 2026
- Financial results for the quarter ended 30th September, 2026. · 05 Nov 2026
- Outcome of the Board Meeting dated 05th November, 2026. · 05 Nov 2026
